Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

ONC

BeOne Medicines Ltd ADR

May 29 • 04:00PM ET

287.92

-2.66 -0.92 %

Healthcare • Biotechnology • Switzerland • Large • NASD

May 29, 6:05 AMBeOne Medicines reports Phase 3 SEQUOIA 78‑month data showing BRUKINSA PFS 71.8% vs 31.0% for bendamustine‑rituximab in treatment‑naive CLL

Peers: REGN VRTX AMGN GILD BIIB ALNY ARGX BMRN ABBV LLY

| Held by: IBB FBT CGGE BBH CGIE CGNG DFAE EMEQ CANC AVEM

Index	-	P/E	64.25	EPS (ttm)	4.48	Insider Own	0.52%	Shs Outstand	102.26M	Perf Week	-7.01%
Market Cap	29.45B	Forward P/E	29.92	EPS next Y	9.62	Insider Trans	-18.19%	Shs Float	101.77M	Perf Month	-0.99%
Enterprise Value	26.67B	PEG	0.43	EPS next Q	1.56	Inst Own	33.65%	Short Float	1.03%	Perf Quarter	-9.17%
Income	514.49M	P/S	5.12	EPS this Y	150.13%	Inst Trans	-1.64%	Short Ratio	4.51	Perf Half Y	-14.10%
Sales	5.76B	P/B	6.72	EPS next Y	46.26%	ROA	7.15%	Short Interest	1.05M	Perf YTD	-5.23%
Book/sh	42.84	P/C	6.09	EPS next 5Y	69.83%	ROE	12.46%	52W High	385.22 -25.26%	Perf Year	16.72%
Cash/sh	47.24	P/FCF	26.36	EPS past 3/5Y	- -	ROIC	7.79%	52W Low	239.25 20.34%	Perf 3Y	21.54%
Dividend Est.	-	EV/EBITDA	31.81	Sales past 3/5Y	55.88% 76.88%	Gross Margin	86.15%	Volatility	2.39% 2.71%	Perf 5Y	-19.69%
Dividend TTM	-	EV/Sales	4.63	EPS Y/Y TTM	225.57%	Oper. Margin	11.95%	ATR (14)	8.81	Perf 10Y	956.20%
Dividend Ex-Date	-	Quick Ratio	3.27	Sales Y/Y TTM	37.70%	Profit Margin	8.94%	RSI (14)	38.62	Recom	1.22
Dividend Gr. 3/5Y	- -	Current Ratio	3.64	EPS Q/Q	17028.70%	SMA20	-5.15%	Beta	0.49	Target Price	412.14
Payout	0.00%	Debt/Eq	0.43	Sales Q/Q	35.67%	SMA50	-4.48%	Rel Volume	0.75	Prev Close	290.58
Employees	12000	LT Debt/Eq	0.39	Earnings	May 06 BMO	SMA200	-10.38%	Avg Volume	231.86K	Price	287.92
IPO	Feb 03, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	27.52% 2.51%	Trades		Volume	174,458	Change	-0.92%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-27-26	Initiated	Wolfe Research	Outperform	$340
Mar-16-26	Downgrade	Jefferies	Buy → Hold	$290
Nov-24-25	Initiated	Truist	Buy
Sep-18-25	Initiated	Barclays	Overweight	$385
Apr-07-25	Initiated	RBC Capital Mkts	Outperform	$312
Mar-03-25	Upgrade	BofA Securities	Neutral → Buy	$207 → $320
Dec-03-24	Resumed	Morgan Stanley	Overweight	$300
Sep-18-24	Initiated	JMP Securities	Mkt Outperform	$288
Feb-06-24	Resumed	JP Morgan	Overweight	$185
Sep-12-23	Initiated	Macquarie	Outperform	$259
Aug-17-23	Initiated	Jefferies	Buy	$287
Jul-17-23	Initiated	Citigroup	Buy	$275
Jun-30-23	Downgrade	Bernstein	Outperform → Mkt Perform	$335 → $196
Jan-12-23	Initiated	Daiwa Securities	Buy	$308
Oct-13-22	Upgrade	SVB Leerink	Mkt Perform → Outperform	$177 → $200
Oct-13-22	Upgrade	Guggenheim	Neutral → Buy	$205
Aug-09-22	Resumed	JP Morgan	Overweight	$296
Mar-17-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$300 → $177
Feb-07-22	Initiated	Deutsche Bank	Buy
Oct-12-21	Initiated	Bernstein	Outperform	$431

Show Previous Ratings

May-29-26 06:00AM	BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026 (Business Wire)
May-27-26 05:00PM	BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026 (Business Wire)
May-26-26 06:01AM	BeOne Medicines to Present at the Goldman Sachs 47th Annual Global Healthcare Conference (Business Wire)
May-21-26 06:00AM	BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts (Business Wire)
May-13-26 01:27PM	BeOne Medicines BEQALZI (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma (Business Wire)
06:00AM	Loading…
May-06-26 06:00AM	BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates (Business Wire) +5.32%
May-04-26 09:43AM	AMD downgraded, Airbnb upgraded: Wall Street's top analyst calls (The Fly)
Apr-29-26 06:00AM	U.S. FDA Grants Priority Review to BeOne Medicines TEVIMBRA in First-Line HER2+ GEA (Business Wire)
Apr-22-26 06:01AM	BeOne Medicines to Announce First Quarter 2026 Financial Results on May 6 (Business Wire)
Mar-03-26 08:02PM	BeOne Medicines Ltd (ONC) Q4 2025 Earnings Call Highlights: Record Growth and Strategic Expansion (GuruFocus.com) -5.51%
Mar-01-26 09:59AM	BeOne Medicines (ONC) Reports $1.5B Revenue for Q4, $1.1B from Lymphoma Treatment (Insider Monkey)
Feb-26-26 09:30AM	Here's What Key Metrics Tell Us About BeOne Medicines Ltd. - Sponsored ADR (ONC) Q4 Earnings (Zacks) -8.48%
06:00AM	BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership (Business Wire)
Feb-17-26 06:00AM	BeOne Medicines to Present at Upcoming Investor Conferences (Business Wire)
Feb-13-26 05:19AM	Bernstein Remains a Buy on BeOne Medicines AG (ONC) (Insider Monkey)
06:00AM	Loading…
Feb-11-26 06:00AM	BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26 (Business Wire)
Feb-02-26 03:10AM	3 Stocks to Buy in February (Motley Fool)
Jan-31-26 09:36AM	Wall Street Bullish on BeOne Medicines AG (ONC) amid Robust Pipeline Development (Insider Monkey)
Jan-30-26 02:07AM	Citizens Highlights BeOne Medicines' (ONC) $3.8B Revenue Potential for 2025 (Insider Monkey)
Jan-29-26 12:28PM	FDA Accepts Summit's Lung Cancer Drug Application, Review Underway (Benzinga)
Jan-13-26 06:00AM	BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference (Business Wire) +5.11%
Jan-07-26 10:22AM	Is the Options Market Predicting a Spike in BeOne Medicines Stock? (Zacks)
Jan-06-26 01:30PM	ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA (Business Wire)
Dec-31-25 08:51AM	Strong Momentum Lifted BeOne Medicines AG (ONC) in Q3 (Insider Monkey)
Dec-23-25 06:01AM	BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-18-25 06:00AM	BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma (Business Wire)
Dec-14-25 03:30AM	Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. (Barrons.com)
Dec-08-25 08:00AM	BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Nave Chronic Lymphocytic Leukemia (Business Wire)
Dec-07-25 06:00PM	Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies (Business Wire)
Nov-28-25 10:07AM	Biotechs Are On A Big Run, And Two Stocks Have Buy Points (Investor's Business Daily)
04:11PM	Loading…
Nov-26-25 04:11PM	Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied (Investor's Business Daily)
Nov-21-25 12:59PM	This Pharma Stock Owned By Top Fund Flirts With Entry As Earnings Surge 452% (Investor's Business Daily)
Nov-20-25 06:00AM	BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025 (Business Wire)
Nov-17-25 08:10AM	Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar. (Barrons.com)
06:00AM	Positive Phase 3 Results Support ZIIHERA as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (Business Wire)
Nov-12-25 04:39PM	Stock Market Today: Dow Hits New Highs; Lilly, Barrick, Goldman Break Out (Live Coverage) (Investor's Business Daily) +9.84%
04:30PM	BeOne, IBD Stock Of The Day, Breaks Out As It Takes On Cancer Giants J&J, AbbVie (Investor's Business Daily)
01:19PM	BeOne Medicines Stock Earns Relative Strength Rating Upgrade (Investor's Business Daily)
12:55PM	IBD Stock Of The Day BeOne Breaks Out As It Takes On Cancer Giants J&J, AbbVie (Investor's Business Daily)
10:31AM	Stock Market Today: Dow Rises But Nasdaq Cools Again As Nvidia, AMD Rally (Live Coverage) (Investor's Business Daily)
Nov-11-25 12:07PM	Biotech Leader BeOne Medicines Eyes New Buy Point As Cancer Drug Sales Surge (Investor's Business Daily)
Nov-10-25 08:03PM	BeOne Medicines Ltd (ONC) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com)
Nov-06-25 11:30AM	BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
06:00AM	BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates (Business Wire)
Oct-28-25 06:01AM	BeOne Medicines to Present at Upcoming Investor Conferences (Business Wire)
Oct-21-25 01:41PM	SMMT's Q3 Loss Wider Than Expected, Stock Down on Study Amendments (Zacks)
Oct-20-25 06:00AM	BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025 (Business Wire)
Oct-13-25 06:00AM	BeOne Medicines Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA (Business Wire)
Oct-03-25 04:21PM	How BeOne Medicines, An IBD 50 Stock, Is Taking On Big Names In Cancer Treatment (Investor's Business Daily)
Oct-02-25 01:35AM	BeOne Medicines (ONC) Gains Barclays Overweight Rating Ahead of Key 2025 Data Readouts (Insider Monkey)
Sep-29-25 10:35AM	Here's Why BeOne Medicines Ltd. (ONC) Declined in Q2 (Insider Monkey)
Sep-18-25 03:00AM	China's Young Consumers Set the Global Trend. What They're Buying Now. (Barrons.com)
Sep-14-25 01:16AM	Citizens JMP Maintains a Buy Rating on BeOne Medicines (ONC) (Insider Monkey)
Sep-12-25 01:01AM	BeOne Medicines (ONC) Reports Positive Phase 1/2 Results for Sonrotoclax in MCL (Insider Monkey)
Sep-10-25 03:55PM	China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order (Investor's Business Daily) -10.59%
Aug-29-25 06:00AM	BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL) (Business Wire)
Aug-28-25 04:55AM	BeOne Medicines Ltd. (ONC) Unveils Promising Breast Cancer Therapies at ASCO 2025 (Insider Monkey)
Aug-27-25 06:00AM	European Commission Approves TEVIMBRA as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025 (Business Wire)
Aug-26-25 06:01AM	BeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference (Business Wire)
Aug-21-25 06:00AM	European Commission Approves Tablet Formulation of BeOne Medicines BRUKINSA for All Approved Indications (Business Wire)
Aug-15-25 12:55PM	This Medical Stock With Blockbuster Cancer Drug Clears Entry Amid 923% Earnings Growth (Investor's Business Daily)
10:04AM	This Eye Treatment Stock Sees Sales Spike 152% As Biotech Leaders Shine (Investor's Business Daily)
Aug-08-25 12:44PM	Hims Stock Gets Booted Off IBD 50 While Other Volatile Names Hang On (Investor's Business Daily)
Aug-06-25 11:30AM	BeOne Medicines Ltd. - Sponsored ADR (ONC) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
06:00AM	BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates (Business Wire)
Jul-31-25 06:00AM	BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstroms Macroglobulinemia (Business Wire)
Jul-28-25 06:00AM	BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA in Neoadjuvant/Adjuvant NSCLC Treatment (Business Wire)
Jul-25-25 10:44PM	BeOne Medicines Ltd. (ONC) Wins EU Nod for Tevimbra (Insider Monkey)
10:06AM	Stevanato (STVN) Soars 10.0%: Is Further Upside Left in the Stock? (Zacks)
Jul-18-25 03:43PM	The S&P 500 and Nasdaq Are Joined By These Stocks Hitting New Highs (Investor's Business Daily)
10:06AM	BeOne Medicines Ltd. - Sponsored ADR (ONC) Surges 4.0%: Is This an Indication of Further Gains? (Zacks)
Jul-16-25 12:58PM	Looming Tariffs Don't Scare This Swiss Cancer Treatment Stock (Investor's Business Daily)
06:00AM	BeOne Medicines to Announce Second Quarter 2025 Financial Results on August 6 (Business Wire)
Jul-10-25 06:00AM	European Commission Approves TEVIMBRA in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma (Business Wire)
Jun-28-25 08:35AM	BeOne Medicines price target raised to $330 from $313 at Morgan Stanley (TipRanks)
Jun-26-25 06:00AM	BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day (Business Wire)
Jun-25-25 06:00AM	BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA (Business Wire)
Jun-12-25 06:00AM	BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025 (Business Wire) +5.38%
Jun-11-25 04:05PM	U.S. FDA Approves Tablet Formulation of BeOnes BRUKINSA for All Approved Indications (Business Wire)
06:01AM	BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025 (Business Wire)
Jun-05-25 02:03PM	Cancer Stock Vaults 40% As Clinical Trial Shows 'Promise'; Sales Reach $1 Billion, Earnings To Triple (Investor's Business Daily)
Jun-02-25 06:00AM	BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025 (Business Wire)
May-31-25 08:00AM	BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSAs Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025 (Business Wire)
May-27-25 08:30AM	BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology (Business Wire)
06:00AM	BeiGene Receives Positive CHMP Opinion for TEVIMBRA as a First-Line Treatment for Nasopharyngeal Cancer (Business Wire)
May-22-25 06:00AM	BeiGene Presents Pioneering Cancer Research at ASCO 2025 Redefining Treatment Across Hematology and Solid Tumors (Business Wire)
May-14-25 04:05PM	BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSAs Leadership and Next-Generation Innovation (Business Wire)
May-13-25 06:01AM	BeiGene to Present at the RBC Capital Markets Global Healthcare Conference (Business Wire)
May-12-25 07:33AM	Trumps Plan to Cut Drug Prices Hits Pfizer, Other Pharma Stocks (The Wall Street Journal)
12:05AM	Trump Drug Plan Hits Pharma Stocks (The Wall Street Journal)
12:05AM	Trump Drug Plan Hits Asian Pharma Stocks (The Wall Street Journal)
May-09-25 07:52AM	BeiGene, Ltd. (ONC): Among Billionaire Lei Zhang's Stock Picks with Huge Upside Potential (Insider Monkey)
May-08-25 01:00PM	BeiGene Ltd (ONC) Q1 2025 Earnings Call Highlights: Achieving Profitability and Expanding ... (GuruFocus.com)
May-07-25 02:05PM	BeiGene targets $4.9B-$5.3B revenue for 2025 with strong BRUKINSA and pipeline growth (Seeking Alpha)
02:04PM	BeiGene, Ltd. (ONC) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:30AM	Compared to Estimates, BeiGene (ONC) Q1 Earnings: A Look at Key Metrics (Zacks)
06:00AM	BeiGene Announces First Quarter 2025 Financial Results and Business Updates (Business Wire)
Apr-29-25 03:32PM	U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene (Business Wire)
01:21PM	Community Health Q1 Earnings Top on Rising Patient Volumes, Stock Up 8% (Zacks)
10:08AM	Universal Health Q1 Earnings Beat on Strong Acute Care Admissions (Zacks)

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

MBAJohn V. Oyler

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Riva Alessandro	Director	May 22 '26	Sale	309.51	212	65,617	0	May 27 05:29 PM
Dugan Margaret	Director	May 22 '26	Sale	309.60	212	65,636	0	May 27 05:26 PM
Sanders Corazon (Corsee) D.	Director	May 22 '26	Sale	309.59	212	65,633	0	May 27 05:26 PM
BAKER BROS. ADVISORS LP	Director	May 22 '26	Sale	23.82	10,998	261,981	142,566	May 27 04:54 PM
MICHAEL GOLLER	Director	May 22 '26	Proposed Sale	310.07	211	65,424		May 22 04:28 PM
RANJEEV KRISHANA	Director	May 22 '26	Proposed Sale	309.28	212	65,567		May 22 04:25 PM
ALESSANDRO RIVA	Director	May 22 '26	Proposed Sale	309.51	212	65,617		May 22 04:22 PM
MARGARET DUGAN	Director	May 22 '26	Proposed Sale	309.60	212	65,636		May 22 04:20 PM
CORAZON D. SANDERS	Director	May 22 '26	Proposed Sale	309.59	212	65,633		May 22 04:18 PM
Lee Chan Henry	SVP, General Counsel	May 13 '26	Option Exercise	191.56	332	63,598	332	May 15 04:39 PM
Lee Chan Henry	SVP, General Counsel	May 13 '26	Sale	310.72	332	103,159	0	May 15 04:39 PM
CHAN LEE	Officer	May 13 '26	Proposed Sale	315.07	1,328	418,413		May 13 04:27 PM
Lee Chan Henry	SVP, General Counsel	Apr 08 '26	Option Exercise	191.56	332	63,598	332	Apr 10 05:40 PM
Lee Chan Henry	SVP, General Counsel	Apr 08 '26	Sale	311.59	332	103,448	0	Apr 10 05:40 PM
Lee Chan Henry	SVP, General Counsel	Mar 11 '26	Option Exercise	191.64	341	65,348	341	Mar 13 05:26 PM
Lee Chan Henry	SVP, General Counsel	Mar 11 '26	Sale	300.00	341	102,300	0	Mar 13 05:26 PM
Lee Chan Henry	SVP, General Counsel	Feb 04 '26	Option Exercise	191.40	1,660	317,721	1,660	Feb 06 04:57 PM
Lee Chan Henry	SVP, General Counsel	Feb 04 '26	Sale	349.52	1,660	580,197	0	Feb 06 04:57 PM
CHAN LEE	Officer	Feb 04 '26	Proposed Sale	346.38	4,676	1,619,673		Feb 04 04:21 PM
Lee Chan Henry	SVP, General Counsel	Jan 07 '26	Option Exercise	191.56	664	127,196	664	Jan 09 05:15 PM
Lee Chan Henry	SVP, General Counsel	Jan 07 '26	Sale	331.76	664	220,289	0	Jan 09 05:15 PM
OYLER JOHN	Chief Executive Officer	Dec 15 '25	Sale	307.79	75,631	23,278,679	24,369	Dec 17 04:47 PM
OYLER JOHN	Chief Executive Officer	Dec 16 '25	Sale	302.87	24,369	7,380,739	0	Dec 17 04:47 PM
JOHN V OYLER	Director	Dec 15 '25	Proposed Sale	319.06	100,000	31,906,000		Dec 15 04:32 PM
Lee Chan Henry	SVP, General Counsel	Dec 10 '25	Option Exercise	191.56	332	63,598	332	Dec 12 04:56 PM
Lee Chan Henry	SVP, General Counsel	Dec 11 '25	Option Exercise	191.56	332	63,598	332	Dec 12 04:56 PM
Lee Chan Henry	SVP, General Counsel	Dec 11 '25	Sale	325.00	332	107,900	0	Dec 12 04:56 PM
Lee Chan Henry	SVP, General Counsel	Dec 10 '25	Sale	318.28	332	105,669	0	Dec 12 04:56 PM
Sanders Corazon (Corsee) D.	Director	Nov 26 '25	Option Exercise	159.03	2,627	417,772	2,627	Dec 01 04:57 PM
Sanders Corazon (Corsee) D.	Director	Nov 26 '25	Sale	340.90	2,627	895,534	0	Dec 01 04:57 PM
CORAZON D. SANDERS	Director	Nov 26 '25	Proposed Sale	340.90	2,627	895,535		Nov 26 04:13 PM
Wu Xiaobin	President and COO	Nov 17 '25	Sale	380.43	3,991	1,518,303	0	Nov 19 04:57 PM
XIAOBIN WU	Officer	Nov 17 '25	Proposed Sale	380.43	3,991	1,518,303		Nov 17 04:16 PM
Wu Xiaobin	President and COO	Nov 12 '25	Sale	356.02	10,000	3,560,161	6,009	Nov 14 05:35 PM
Wu Xiaobin	President and COO	Nov 13 '25	Sale	380.54	6,009	2,286,660	0	Nov 14 05:35 PM
Lee Chan Henry	SVP, General Counsel	Nov 12 '25	Option Exercise	191.47	996	190,704	996	Nov 14 05:28 PM
Lee Chan Henry	SVP, General Counsel	Nov 12 '25	Sale	349.17	996	347,770	0	Nov 14 05:28 PM
XIAOBIN WU	Officer	Nov 13 '25	Proposed Sale	380.54	6,009	2,286,659		Nov 13 04:22 PM
XIAOBIN WU	Officer	Nov 12 '25	Proposed Sale	356.02	10,000	3,560,161		Nov 12 05:04 PM
Lee Chan Henry	SVP, General Counsel	Oct 08 '25	Option Exercise	211.04	9,559	2,017,363	9,559	Oct 10 04:56 PM
Lee Chan Henry	SVP, General Counsel	Oct 08 '25	Sale	350.40	10,671	3,739,108	0	Oct 10 04:56 PM
CHAN LEE	Officer	Oct 08 '25	Proposed Sale	341.62	13,659	4,666,188		Oct 08 04:19 PM
OYLER JOHN	Chief Executive Officer	Sep 16 '25	Sale	325.71	27,803	9,055,694	0	Sep 18 04:45 PM
PAN-OYLER FOUNDATION	Director	Sep 16 '25	Proposed Sale	332.27	1,204	400,053		Sep 16 04:25 PM
JOHN V OYLER	Director	Sep 16 '25	Proposed Sale	332.27	27,803	9,238,103		Sep 16 04:22 PM
Lee Chan Henry	SVP, General Counsel	Sep 10 '25	Option Exercise	197.10	8,894	1,752,981	8,894	Sep 12 04:38 PM
Lee Chan Henry	SVP, General Counsel	Sep 10 '25	Sale	325.53	10,006	3,257,289	0	Sep 12 04:38 PM
Wang Lai	Global Head of R&D	Sep 09 '25	Sale	350.06	5,000	1,750,312	0	Sep 11 05:10 PM
CHAN LEE	Officer	Sep 10 '25	Proposed Sale	351.13	9,010	3,163,681		Sep 10 04:37 PM
Sanders Corazon (Corsee) D.	Director	Sep 05 '25	Option Exercise	155.68	2,665	414,887	2,665	Sep 09 05:31 PM
Sanders Corazon (Corsee) D.	Director	Sep 05 '25	Sale	337.00	2,665	898,105	0	Sep 09 05:31 PM
WANG HOLDINGS LLC	Officer	Sep 09 '25	Proposed Sale	346.45	5,000	1,732,250		Sep 09 04:28 PM
CORAZON D. SANDERS	Director	Sep 05 '25	Proposed Sale	337.00	2,665	898,105		Sep 05 04:02 PM
Ball Titus B.	Principal Accounting Officer	Sep 02 '25	Sale	326.76	122	39,865	0	Sep 04 05:29 PM
TITUS BENJAMIN BALL	Officer	Sep 02 '25	Proposed Sale	326.76	122	39,865		Sep 02 04:26 PM
Wu Xiaobin	President and COO	Aug 13 '25	Option Exercise	164.24	49,858	8,188,887	49,858	Aug 15 04:40 PM
Wu Xiaobin	President and COO	Aug 14 '25	Option Exercise	156.45	39,936	6,247,989	39,936	Aug 15 04:40 PM
Wu Xiaobin	President and COO	Aug 13 '25	Sale	304.16	49,858	15,164,818	0	Aug 15 04:40 PM
Wu Xiaobin	President and COO	Aug 14 '25	Sale	305.06	39,936	12,182,818	0	Aug 15 04:40 PM
Lee Chan Henry	SVP, General Counsel	Aug 13 '25	Option Exercise	177.90	8,230	1,464,080	8,230	Aug 15 04:38 PM
Lee Chan Henry	SVP, General Counsel	Aug 13 '25	Sale	300.45	11,013	3,308,877	0	Aug 15 04:38 PM
XIAOBIN WU	Officer	Aug 13 '25	Proposed Sale	288.10	89,794	25,869,651		Aug 13 04:30 PM
CHAN LEE	Officer	Aug 13 '25	Proposed Sale	288.10	10,338	2,978,378		Aug 13 04:28 PM
Rosenberg Aaron	Chief Financial Officer	Aug 01 '25	Sale	290.47	1,190	345,659	0	Aug 05 05:16 PM
AARON ROSENBERG	Officer	Aug 01 '25	Proposed Sale	290.47	1,190	345,659		Aug 01 04:21 PM
Wang Lai	Global Head of R&D	Jul 29 '25	Sale	302.49	4,041	1,222,380	259	Jul 31 05:05 PM
Wang Lai	Global Head of R&D	Jul 30 '25	Sale	305.00	259	78,995	0	Jul 31 05:05 PM
Lee Chan Henry	SVP, General Counsel	Jul 30 '25	Sale	304.60	920	280,233	0	Jul 31 05:04 PM
CHAN LEE	Officer	Jul 30 '25	Proposed Sale	304.60	920	280,233		Jul 30 04:07 PM
Wang Lai	Global Head of R&D	Jul 18 '25	Sale	300.00	700	210,000	0	Jul 22 04:54 PM
WANG HOLDINGS LLC	Officer	Jul 18 '25	Proposed Sale	290.35	5,000	1,451,750		Jul 18 04:46 PM
OYLER JOHN	Chief Executive Officer	Jul 09 '25	Sale	253.38	27,802	7,044,591	0	Jul 11 05:14 PM
JOHN V OYLER	Director	Jul 09 '25	Proposed Sale	244.47	27,802	6,796,755		Jul 09 04:15 PM
PAN-OYLER FOUNDATION	Director	Jul 08 '25	Proposed Sale	240.99	1,661	400,284		Jul 08 04:21 PM
Wang Lai	Global Head of R&D	Jun 23 '25	Sale	260.00	1,028	267,280	0	Jun 25 05:09 PM
Wu Xiaobin	President and COO	Jun 23 '25	Sale	260.00	1,363	354,380	0	Jun 25 05:08 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Jun 24 '25	Sale	265.50	2,007	532,867	0	Jun 25 05:08 PM
OYLER JOHN	Chief Executive Officer	Jun 23 '25	Sale	261.61	3,174	830,360	0	Jun 25 05:06 PM
XIAODONG WANG	Director	Jun 24 '25	Proposed Sale	257.51	2,007	516,823		Jun 24 04:25 PM
LAI WANG	Officer	Jun 23 '25	Proposed Sale	260.00	1,028	267,280		Jun 23 04:09 PM
XIAOBIN WU	Officer	Jun 23 '25	Proposed Sale	260.00	1,363	354,380		Jun 23 04:08 PM
JOHN OYLER	Officer	Jun 23 '25	Proposed Sale	261.61	3,174	830,360		Jun 23 04:08 PM
Lee Chan Henry	SVP, General Counsel	Jun 16 '25	Sale	266.50	422	112,463	0	Jun 18 05:12 PM
Wang Lai	Global Head of R&D	Jun 16 '25	Sale	266.40	1,177	313,558	470	Jun 18 05:10 PM
Wang Lai	Global Head of R&D	Jun 17 '25	Sale	251.37	470	118,142	0	Jun 18 05:10 PM
Wu Xiaobin	President and COO	Jun 16 '25	Sale	265.52	1,543	409,694	630	Jun 18 05:08 PM
Wu Xiaobin	President and COO	Jun 17 '25	Sale	250.87	630	158,047	0	Jun 18 05:08 PM
OYLER JOHN	Chief Executive Officer	Jun 16 '25	Sale	266.05	3,680	979,046	1,460	Jun 18 05:06 PM
OYLER JOHN	Chief Executive Officer	Jun 17 '25	Sale	256.49	1,460	374,473	0	Jun 18 05:06 PM
JOHN OYLER	Officer	Jun 17 '25	Proposed Sale	256.49	1,460	374,473		Jun 17 04:20 PM
LAI WANG	Officer	Jun 17 '25	Proposed Sale	251.37	470	118,142		Jun 17 04:19 PM
XIAOBIN WU	Officer	Jun 17 '25	Proposed Sale	250.87	630	158,047		Jun 17 04:18 PM
XIAOBIN WU	Officer	Jun 16 '25	Proposed Sale	266.52	1,543	411,237		Jun 16 04:16 PM
CHAN LEE	Officer	Jun 16 '25	Proposed Sale	266.50	422	112,463		Jun 16 04:15 PM
JOHN OYLER	Officer	Jun 16 '25	Proposed Sale	266.05	3,680	979,046		Jun 16 04:14 PM
LAI WANG	Officer	Jun 16 '25	Proposed Sale	266.40	1,177	313,558		Jun 16 04:03 PM
Ball Titus B.	Principal Accounting Officer	Jun 11 '25	Sale	258.36	134	34,620	0	Jun 12 05:51 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Jun 10 '25	Option Exercise	6.50	41,760	271,440	41,760	Jun 12 05:39 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Jun 10 '25	Sale	262.82	41,760	10,975,316	0	Jun 12 05:39 PM
TITUS BENJAMIN BALL	Officer	Jun 11 '25	Proposed Sale	258.36	134	34,620		Jun 11 04:15 PM

Open in Screener

SDGR

Schrodinger Inc

May 29 • 04:00PM ET

15.20

+1.04 7.34 %

Healthcare • Health Information Services • USA • Small • NASD

Peers: CERT VEEV RXRX ABSI PHR ICLR IQV GH MEDP AI

| Held by: IJR ARKG VTI IWM VB VBK VXF SPSM IJT IWO

Index	RUT	P/E	-	EPS (ttm)	-1.40	Insider Own	15.51%	Shs Outstand	65.38M	Perf Week	14.89%
Market Cap	1.14B	Forward P/E	-	EPS next Y	-1.25	Insider Trans	-0.87%	Shs Float	63.34M	Perf Month	29.25%
Enterprise Value	836.30M	PEG	-	EPS next Q	-0.49	Inst Own	89.10%	Short Float	16.21%	Perf Quarter	26.04%
Income	-103.48M	P/S	4.46	EPS this Y	-43.82%	Inst Trans	-4.94%	Short Ratio	7.87	Perf Half Y	-12.89%
Sales	254.91M	P/B	3.61	EPS next Y	38.19%	ROA	-15.03%	Short Interest	10.27M	Perf YTD	-14.99%
Book/sh	4.21	P/C	2.79	EPS next 5Y	63.20%	ROE	-30.12%	52W High	27.63 -44.99%	Perf Year	-29.10%
Cash/sh	5.44	P/FCF	-	EPS past 3/5Y	12.46% -28.10%	ROIC	-25.58%	52W Low	10.94 38.88%	Perf 3Y	-57.78%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	12.24% 18.81%	Gross Margin	55.33%	Volatility	6.53% 5.65%	Perf 5Y	-78.34%
Dividend TTM	-	EV/Sales	3.28	EPS Y/Y TTM	46.79%	Oper. Margin	-64.65%	ATR (14)	0.75	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.74	Sales Y/Y TTM	10.59%	Profit Margin	-40.60%	RSI (14)	74.54	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	2.74	EPS Q/Q	0.89%	SMA20	17.41%	Beta	1.62	Target Price	20.88
Payout	-	Debt/Eq	0.34	Sales Q/Q	-1.62%	SMA50	24.08%	Rel Volume	1.79	Prev Close	14.16
Employees	850	LT Debt/Eq	0.29	Earnings	May 05 AMC	SMA200	-5.69%	Avg Volume	1.31M	Price	15.20
IPO	Feb 06, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-29.93% 23.15%	Trades		Volume	2,337,405	Change	7.34%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-15-25	Upgrade	BofA Securities	Neutral → Buy	$24
Sep-30-25	Initiated	Goldman	Neutral	$19
Aug-15-25	Downgrade	Citigroup	Buy → Neutral	$20
Aug-14-25	Initiated	Barclays	Overweight	$25
Jul-03-25	Resumed	Morgan Stanley	Equal-Weight	$28
Jul-02-24	Initiated	Leerink Partners	Outperform	$29
Dec-05-23	Initiated	KeyBanc Capital Markets	Overweight	$38
May-05-23	Resumed	Piper Sandler	Overweight	$60
Dec-19-22	Initiated	Goldman	Neutral	$23
Mar-01-22	Initiated	Citigroup	Buy	$55
Nov-19-21	Initiated	Piper Sandler	Overweight	$87
Nov-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$82 → $49
Nov-11-21	Downgrade	BofA Securities	Buy → Neutral	$80 → $52
Oct-13-21	Initiated	Berenberg	Buy	$91
Sep-01-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$82
May-25-21	Initiated	Craig Hallum	Buy	$85
Nov-23-20	Upgrade	BofA Securities	Neutral → Buy	$74
Oct-12-20	Upgrade	Jefferies	Hold → Buy
Mar-02-20	Initiated	Morgan Stanley	Equal-Weight	$43
Mar-02-20	Initiated	Jefferies	Hold	$42

Show Previous Ratings

May-22-26 08:30AM	Schrdinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-06-26 08:30AM	Schrödinger, Inc. Q1 2026 Earnings Call Summary (Moby)
May-05-26 04:05PM	Schrdinger Reports First Quarter 2026 Financial Results (Business Wire)
May-04-26 08:30AM	Schrodinger to Participate in Upcoming Investor Conferences (Business Wire)
Apr-21-26 08:30AM	Schrdinger to Announce First Quarter 2026 Financial Results on May 5 (Business Wire)
08:30AM	Loading…
Apr-17-26 08:30AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-18-26 08:30AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-02-26 12:13PM	Can AI Acceleration and R&D Strength Drive VEEV Ahead of Q4 Earnings? (Zacks)
02:57AM	Schrodinger, Inc. (SDGR) Transition to Licensing Model Triggers Robust Revenue Growth (Insider Monkey)
Feb-26-26 08:30AM	Schrödinger, Inc. Q4 2025 Earnings Call Summary (Moby) +8.14%
03:08AM	Schrodinger Q4 Earnings Call Highlights (MarketBeat)
12:03AM	Schrodinger Inc (SDGR) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid Transition ... (GuruFocus.com)
Feb-25-26 04:05PM	Schrdinger Reports Fourth Quarter and Full-Year 2025 Financial Results (Business Wire)
10:00AM	Nvidia Earnings Slam Into Market With No Patience for AI Hiccups (Bloomberg)
Feb-24-26 08:30AM	Schrodinger to Participate in Upcoming Investor Conferences (Business Wire)
08:30AM	Loading…
Feb-18-26 08:30AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-12-26 05:30PM	10x Genomics (TXG) Reports Q4 Loss, Beats Revenue Estimates (Zacks) -5.59%
Feb-11-26 08:30AM	Schrdinger to Announce Fourth Quarter and Full-Year 2025 Financial Results on February 25 (Business Wire) -12.11%
Feb-03-26 03:38AM	TruBridge (TBRG) Surges 5.6%: Is This an Indication of Further Gains? (Zacks) -5.04%
Jan-29-26 09:25AM	AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift (PR Newswire)
Jan-12-26 08:30AM	Schrodinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities (Business Wire)
Jan-09-26 07:00AM	Schrodinger Partners with Lilly to Make TuneLab Platform Available in LiveDesign (Business Wire)
Jan-07-26 12:24PM	BFLY to Extend 3D Imaging Capabilities to Butterfly Garden Developers (Zacks)
Jan-02-26 12:10PM	CapsoVision Submits FDA 510(k) for AI-Assisted Module in CapsoCam Plus (Zacks)
Dec-31-25 10:30AM	KRMD Submits 510(k) to Use FreedomEDGE System With Oncology Biologic (Zacks)
Dec-23-25 12:35PM	FLGT to Acquire Bako & StrataDx Assets to Expand Pathology Platform (Zacks)
09:48AM	Do Options Traders Know Something About Schrodinger Stock We Don't? (Zacks)
Dec-22-25 09:53AM	BofA Upgrades Schrodinger (SDGR) to Buy After Strategic Pivot to Software (Insider Monkey) +9.80%
Dec-20-25 06:35AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Dec-17-25 08:30AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:55AM	Loading…
Dec-12-25 09:55AM	Wall Street Analysts Believe Schrodinger (SDGR) Could Rally 46.17%: Here's is How to Trade (Zacks)
Dec-09-25 11:57AM	Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions (PR Newswire)
Nov-10-25 09:55AM	Here's Why Schrodinger (SDGR) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Nov-07-25 02:26AM	Schrodinger (SDGR) and Copernic Catalysts Surpass the Final Technical Milestone for Neptune (Insider Monkey)
Nov-06-25 08:30AM	Schrodinger to Present at Jefferies London Healthcare Conference (Business Wire) -5.67%
12:06AM	Schrodinger Inc (SDGR) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic Shifts ... (GuruFocus.com)
Nov-05-25 06:40PM	Schrodinger, Inc. (SDGR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Schrdinger Reports Third Quarter 2025 Financial Results (Business Wire)
07:15AM	Meta Slumps on AI Spending, Echoing 2022 Metaverse Rout (Bloomberg)
Nov-04-25 05:45PM	Tempus AI (TEM) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:58AM	Earnings To Watch: Schrodinger Inc (SDGR) Reports Q3 2025 Result (GuruFocus.com)
Oct-30-25 07:30AM	Copernic Catalysts Announces Achievement of Ammonia Catalyst Milestone in Research Collaboration with Schrodinger (Business Wire)
Oct-22-25 08:30AM	Schrodinger to Announce Third Quarter 2025 Financial Results on November 5 (Business Wire)
Oct-21-25 07:05AM	Strength Seen in Schrodinger (SDGR): Can Its 13.8% Jump Turn into More Strength? (Zacks) -5.05%
Oct-15-25 08:30AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.07%
Sep-18-25 08:30AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-09-25 09:55AM	Does Schrodinger (SDGR) Have the Potential to Rally 40.43% as Wall Street Analysts Expect? (Zacks)
Aug-27-25 08:30AM	Schrodinger to Present at Morgan Stanley Global Healthcare Conference (Business Wire)
Aug-15-25 04:30PM	Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
04:30PM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-14-25 07:00AM	Schrödinger Announces Discontinuation of SGR-2921 Program (Business Wire)
07:00AM	Schrodinger Announces Discontinuation of SGR-2921 Program (Business Wire)
Aug-06-25 06:30PM	Schrodinger, Inc. (SDGR) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
04:05PM	Schrdinger Reports Second Quarter 2025 Financial Results (Business Wire)
Aug-05-25 06:05PM	Clover Health Investments, Corp. (CLOV) Q2 Earnings Meet Estimates (Zacks)
09:52AM	Earnings To Watch: Schrodinger Inc (SDGR) Reports Q2 2025 Result (GuruFocus.com)
Aug-01-25 12:08PM	Can Veeva's Vault R&D Keep Its Lead Amid Rising AI Competition? (Zacks)
Jul-25-25 08:30AM	Schrödinger to Announce Second Quarter 2025 Financial Results on August 6 (Business Wire)
08:30AM	Schrodinger to Announce Second Quarter 2025 Financial Results on August 6 (Business Wire)
Jul-24-25 10:00AM	Analysts Estimate Omnicell (OMCL) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-23-25 10:02AM	Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses? (Zacks)
10:00AM	Schrodinger, Inc. (SDGR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-18-25 08:00AM	Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:00AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-17-25 08:00AM	Ajax Therapeutics and Schrdinger Expand Research Collaboration to Include Additional JAK Target (Business Wire)
Jul-16-25 09:58AM	Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? (Zacks)
Jul-10-25 12:39AM	Morgan Stanley Assumes Coverage on Schrodinger (SDGR) Stock (Insider Monkey)
Jul-07-25 10:23AM	Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith? (Zacks)
Jul-04-25 09:45AM	Meta upgraded, PNC Financial downgraded: Wall Streets top analyst calls (TipRanks)
Jul-03-25 09:41AM	Meta upgraded, PNC Financial downgraded: Wall Street's top analyst calls (The Fly)
08:35AM	MS initiates coverage on AI Biotechs, flags key pipeline catalysts (Investing.com)
Jul-02-25 10:28AM	Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process? (Zacks)
10:05AM	VEEV Integrates GenAI in Vault Platform to Drive Workflow Automation (Zacks)
Jun-27-25 08:00AM	Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia (Business Wire)
08:00AM	Schrodinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenstrom Macroglobulinemia (Business Wire)
Jun-17-25 08:30AM	Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:30AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-12-25 07:00AM	Schrdinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress (Business Wire) -14.44%
May-29-25 05:00PM	Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer (Business Wire)
05:00PM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer (Business Wire)
08:00AM	Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing (Business Wire)
08:00AM	Schrodinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing (Business Wire)
May-27-25 10:00AM	RXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside? (Zacks)
May-23-25 08:30AM	Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:30AM	Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-22-25 08:30AM	Schrödinger to Present at Jefferies Global Healthcare Conference (Business Wire)
08:30AM	Schrodinger to Present at Jefferies Global Healthcare Conference (Business Wire)
May-21-25 04:26AM	Leadership Transition at Schrodinger: Richie Jain Named CFO (Insider Monkey)
May-20-25 07:00AM	Tourmaline shares fall on Phase 2 data; Schrödinger cuts staff (BioPharma Dive) -8.62%
06:30AM	Schrödinger Announces CFO Appointment (Business Wire)
06:30AM	Schrodinger Announces CFO Appointment (Business Wire)
May-14-25 09:30AM	Schrdinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma (Business Wire)
May-08-25 07:42AM	Q1 2025 Schrodinger Inc Earnings Call (Thomson Reuters StreetEvents)
03:31AM	Schrodinger Inc (SDGR) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ... (GuruFocus.com)
May-07-25 06:40PM	Schrodinger, Inc. (SDGR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:00PM	Schrodinger projects strong 2025 revenue growth with $45M-$50M in drug discovery (Seeking Alpha)
05:59PM	Schrodinger, Inc. (SDGR) Q1 2025 Earnings Call Transcript (Seeking Alpha)
04:05PM	Schrdinger Reports Strong First Quarter 2025 Financial Results (Business Wire)
10:00AM	Here are the major earnings after the close today (Seeking Alpha)
May-06-25 05:15PM	Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -9.31%

Schrodinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software segment sells software to transform drug discovery across the life sciences industry and to customers in materials science industries. The Drug Discovery segment offers diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The company was founded by Richard A. Friesner, William A. Goddard, III and Murco Ringnalda in 1990 and is headquartered in New York, NY.

CEODr. Ramy Farid Ph.D.

PresidentDr. Karen Akinsanya Ph.D.

Co-FounderDr. Richard A. Friesner Ph.D.

Executive VPMr. Richie Jain

Corporate SecretaryMs. Yvonne Tran Esq.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Herman Jenny	Officer	May 01 '26	Proposed Sale	12.26	1,957	24,000		May 01 03:18 PM
Farid Ramy	President & CEO	Apr 17 '26	Option Exercise	3.07	117,527	360,808	405,351	Apr 17 06:09 PM
Farid Ramy	President & CEO	Apr 16 '26	Option Exercise	3.07	43,000	132,010	373,824	Apr 17 06:09 PM
Farid Ramy	President & CEO	Apr 16 '26	Sale	12.33	43,000	530,233	330,824	Apr 17 06:09 PM
Farid Ramy	President & CEO	Apr 17 '26	Sale	12.21	43,000	524,944	330,824	Apr 17 06:09 PM
Jain Rachit	EVP & CFO	Apr 16 '26	Sale	12.75	844	10,758	51,752	Apr 17 06:07 PM
RAMY SAMIR FARID	Director	Apr 16 '26	Proposed Sale	12.40	86,000	1,066,400		Apr 16 04:14 PM
Jain Rachit	Officer	Apr 16 '26	Proposed Sale	12.75	844	10,758		Apr 16 03:10 PM
Herman Jenny	CAO	Mar 05 '26	Sale	12.85	775	9,956	35,412	Mar 06 05:29 PM
Herman Jenny	CAO	Mar 06 '26	Sale	12.84	608	7,808	34,804	Mar 06 05:29 PM
Jain Rachit	EVP & CFO	Mar 05 '26	Sale	12.90	1,631	21,033	52,596	Mar 06 05:29 PM
Tran Yvonne	EVP, CLO & CPO	Mar 05 '26	Sale	12.89	1,094	14,107	52,683	Mar 06 05:28 PM
Farid Ramy	President & CEO	Mar 05 '26	Sale	12.91	3,661	47,249	330,824	Mar 06 05:28 PM
Akinsanya Karen	See Remarks	Mar 05 '26	Sale	12.90	1,366	17,625	69,956	Mar 06 05:27 PM
Lorton Kenneth Patrick	EVP, CTO & COO, Software	Mar 05 '26	Sale	12.90	1,222	15,761	89,241	Mar 06 05:26 PM
Abel Robert Lorne	See Remarks	Mar 04 '26	Sale	12.81	1,300	16,653	55,897	Mar 06 05:26 PM
Herman Jenny	Officer	Mar 06 '26	Proposed Sale	12.84	608	7,808		Mar 06 03:18 PM
Lorton Kenneth Patrick	Officer	Mar 05 '26	Proposed Sale	12.90	1,222	15,762		Mar 05 03:27 PM
Tran Yvonne	Officer	Mar 05 '26	Proposed Sale	12.89	1,094	14,107		Mar 05 03:16 PM
Herman Jenny	Officer	Mar 05 '26	Proposed Sale	12.85	775	9,955		Mar 05 03:16 PM
Farid Ramy	Officer	Mar 05 '26	Proposed Sale	12.91	3,661	47,248		Mar 05 03:14 PM
Jain Rachit	Officer	Mar 05 '26	Proposed Sale	12.90	1,631	21,034		Mar 05 03:07 PM
Akinsanya Karen	Officer	Mar 05 '26	Proposed Sale	12.90	1,366	17,625		Mar 05 03:05 PM
Robert Abel	Officer	Mar 04 '26	Proposed Sale	12.73	1,300	16,549		Mar 04 10:21 AM
Farid Ramy	Officer	Mar 02 '26	Proposed Sale	11.90	5,560	66,151		Mar 02 05:06 PM
Akinsanya Karen	Officer	Mar 02 '26	Proposed Sale	11.99	2,206	26,454		Mar 02 04:35 PM
Tran Yvonne	EVP, CLO & CPO	Feb 10 '26	Sale	13.80	776	10,705	22,859	Feb 12 04:23 PM
Lorton Kenneth Patrick	EVP, CTO & COO, Software	Feb 10 '26	Sale	13.73	925	12,704	52,651	Feb 12 04:22 PM
Herman Jenny	CAO	Feb 10 '26	Sale	13.79	752	10,370	26,597	Feb 12 04:21 PM
Abel Robert Lorne	See Remarks	Feb 09 '26	Sale	13.51	1,230	16,617	19,385	Feb 11 06:00 PM
Herman Jenny	Officer	Feb 10 '26	Proposed Sale	13.79	752	10,370		Feb 10 03:40 PM
Lorton Kenneth Patrick	Officer	Feb 10 '26	Proposed Sale	13.73	925	12,704		Feb 10 03:35 PM
Tran Yvonne	Officer	Feb 10 '26	Proposed Sale	13.80	776	10,705		Feb 10 03:29 PM
Robert Abel	Officer	Feb 09 '26	Proposed Sale	13.43	1,230	16,519		Feb 09 03:21 PM
Dugan Margaret	Chief Medical Officer	Oct 16 '25	Sale	21.07	1,395	29,387	24,574	Oct 17 04:28 PM
Dugan Margaret	Officer	Oct 16 '25	Proposed Sale	21.07	1,395	29,387		Oct 16 03:16 PM

ONC

BeOne Medicines Ltd ADR

SDGR

Schrodinger Inc

Upgrade your Finviz experience